A transdermal patch delivers a drug through the skin and into the bloodstream at a controlled rate, and building one requires assembling a few key layers: a backing, a drug reservoir or matrix, an adhesive, and optionally a rate-controlling membrane. The basic concept is straightforward, but the details of drug selection, material choices, and manufacturing technique determine whether a patch actually works. Here’s how the process comes together from formulation to finished product.
Core Components of a Patch
Every transdermal patch is a laminated structure with distinct layers, each serving a specific purpose. The outermost layer is the backing, an impermeable film (usually made of polyester or polyethylene) that protects the drug from the environment and prevents it from leaking outward. Beneath that sits the drug itself, either dissolved or suspended in a reservoir or embedded directly into a polymer matrix. On the skin-facing side, a pressure-sensitive adhesive holds the patch in place and, in some designs, also contains the drug. Before application, a peel-away release liner protects the adhesive.
Some patches also include a rate-controlling membrane, a thin semi-permeable barrier between the drug reservoir and the adhesive layer. This membrane governs how fast the drug reaches the skin, acting as a bottleneck that smooths out delivery over hours or days.
Two Main Patch Designs
The two dominant architectures are the matrix system and the reservoir system, and the choice between them shapes every downstream manufacturing decision.
In a drug-in-adhesive matrix system, the drug is mixed directly into the adhesive polymer. The result is the simplest patch structure: just a backing layer, the drug-loaded adhesive, and a release liner. Because there are fewer layers, these patches tend to be thinner, more flexible, and easier to manufacture. Most modern commercial patches use this design.
In a reservoir system, the drug sits in a separate compartment, often as a solution, suspension, or gel, held between the backing and a rate-controlling membrane. The membrane meters the drug out at a predictable rate. These patches are more complex to assemble but offer tighter control over release kinetics, which matters for drugs with a narrow therapeutic window.
Choosing the Right Drug
Not every drug can cross the skin effectively. The outermost layer of skin, the stratum corneum, is a formidable barrier, and only molecules with specific physical properties can penetrate it at useful rates.
The ideal transdermal drug candidate has a molecular weight below 400 daltons, small enough to navigate the tightly packed lipid layers of the skin. It needs a balanced ability to dissolve in both water and oil, reflected by a log P (a measure of fat-versus-water preference) between negative 1.0 and 4. The melting point should stay below 200°C, and the required daily dose should be low, generally under 20 milligrams per day. Drugs with short half-lives (10 hours or less) and low oral bioavailability are especially good candidates, since a patch can maintain steady blood levels that oral dosing can’t.
Crucially, the drug must not irritate or sensitize the skin. Even a pharmacologically perfect molecule is useless as a patch if it causes redness, swelling, or allergic reactions at the application site.
The Solvent Casting Process
The most common lab and small-scale manufacturing method for matrix patches is solvent casting. It works in a logical sequence of dissolving, pouring, and drying.
First, you dissolve the polymer base in a suitable solvent. Common polymers include polyvinyl alcohol and polyvinylpyrrolidone, and the solvent is often a water-ethanol mixture. Once the polymer solution is clear, you dissolve the active drug into it, typically at a defined weight percentage (10% by weight is a common starting point in research formulations). Plasticizers like propylene glycol or polyethylene glycol 400 are then added to keep the dried film flexible rather than brittle.
Next, you pour the homogeneous solution into a mold or onto a flat surface lined with release material. In research settings, multi-well plates or glass petri dishes work for casting small circular patches. The cast films are then dried at a controlled temperature, often around 40°C, until the solvent evaporates and a solid, flexible film remains. After drying, the films are peeled from the mold and cut to the desired size and shape. In industrial production, this cutting step uses precision die-cutting equipment to stamp out uniform patches, which are then laminated with a backing layer and sealed with a release liner.
Boosting Skin Permeation
Many drugs that meet the basic criteria still don’t cross the skin fast enough on their own. Chemical permeation enhancers solve this by temporarily disrupting the lipid structure of the stratum corneum, creating easier pathways for drug molecules.
Hundreds of enhancer compounds exist, but they fall into a few major families. Fatty acids (oleic acid is the most widely used) integrate into the skin’s natural lipid layers and create disorder that increases permeability. Alcohols and glycols improve drug solubility in the skin and pull moisture into the stratum corneum, loosening its structure. Terpenes, naturally derived from plants (menthol is a familiar example), are effective enhancers with a relatively gentle safety profile. Sulfoxides and surfactants are also used, though they carry a higher risk of irritation at effective concentrations.
As of 2021, researchers had catalogued 649 distinct chemical permeation enhancers. The practical challenge is finding one that boosts absorption enough to be useful without causing skin reactions over the days a patch is typically worn.
Selecting the Adhesive
The adhesive is arguably the most underappreciated component. It has to stick to skin reliably for the full wear period (often 24 to 72 hours), peel off without causing pain or leaving residue, remain chemically compatible with the drug, and not irritate the skin.
Three classes of pressure-sensitive adhesive dominate commercial patches. Acrylics are the most versatile and widely used, offering good compatibility with a broad range of drugs and excellent moisture resistance. Silicone adhesives are gentler on sensitive skin and work well for patches that need frequent reapplication to the same area. Polyisobutylene adhesives have strong initial tack and are common in older patch designs. Choosing among them depends on the drug’s chemistry, since some drugs dissolve well in acrylics but degrade in silicones, or vice versa.
Quality and Safety Testing
A finished patch must pass several performance tests before it can reach a patient. The FDA evaluates adhesion using a five-point scoring scale: a score of 0 means 90% or more of the patch surface remains adhered to the skin (essentially no lift), while a score of 4 means the patch has completely fallen off. For a generic patch to be approved, its average adhesion score must be statistically noninferior to the brand-name product, with a tight margin of just 0.15 points on that scale.
Skin irritation testing follows a structured protocol as well. Evaluators score two dimensions at each patch change: the dermal response (ranging from 0 for no irritation up to 7 for a strong reaction spreading beyond the patch site) and secondary effects like glazing, peeling, cracking, or fissures (scored from 0 to 3). These scores are combined into a mean irritation score that serves as the primary safety endpoint. A patch that consistently causes visible redness or papules will fail this evaluation regardless of how well it delivers the drug.
Microneedle Patches for Larger Molecules
Traditional patches are limited to small, fat-soluble molecules. Proteins, vaccines, and other large molecules simply can’t cross the stratum corneum passively. Microneedle patches bypass this barrier entirely by using arrays of tiny needles, typically a few hundred micrometers tall, that painlessly puncture the outermost skin layer and deposit drug directly into the layers beneath.
Dissolving microneedle patches are made from water-soluble, biodegradable polymers. The drug is loaded into the needle tips, and after insertion, the needles dissolve within minutes, releasing their payload. These are typically fabricated using a micro-mold method: a master mold (increasingly made with commercial 3D printers) defines the needle geometry, and a two-step casting process fills the needle cavities with drug-loaded polymer before adding a backing layer. Hollow microneedle arrays, made by electrodeposition of metal onto polymer molds, can deliver even larger volumes of liquid formulation through their open channels.
3D printing has dramatically lowered the barrier to prototyping microneedle molds, making it possible to iterate on needle length, density, and geometry without expensive cleanroom fabrication. This has opened up custom manufacturing possibilities that didn’t exist even a few years ago.